• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senzer Pharmaceuticals wins CE Mark for cannabinoid inhaler

September 18, 2019 By Sean Whooley

Senzer Pharmaceuticals said yesterday that it has received the CE Mark for its cannabinoid inhaler.

London-based Senzer said the Class IIa medical device approval, obtained in a joint project with manufacturing partner Europlaz, is the first-ever granted in the cannabinoid space and will allow the company to accelerate its plans to launch in the UK and other European countries this year.

The breath-activated inhaler is designed to deliver synthetic cannabinoids as a fine mist from a pressurized canister, releasing into the lungs. Senzer said the device will allow patients to control dosing as well.

The company said development up to this point has focused on CBD and THC delivery, and it plans to use specific rations of the chemicals to give professionals flexibility in treatment.

“Many patients have been approaching their doctors to seek cannabinoid treatment, and doctors have understandably been wanting clarity on which cannabinoids are available, how to ensure a controlled dose, and whether the actives are validated and supported by clinical evidence,” CEO Alex Hearn said in a news release. “We believe with our inhaler we can provide answers to some of these key questions.”

“Launching into the Specials arena will give us some real insight into what conditions people are requesting treatment for, and to evaluate which may be the most optimal formulations for these conditions,” added quality director Lester Gleeson. “This will, in turn, inform our clinical trial program as we work to develop fully licensed medicines.”

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: Europlaz, Senzer Pharmaceuticals

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS